Ultrasound-mediated immune regulation in tumor immunotherapy

Sun, Shijie; Tang, Qinglian; Sun, Lihong; Zhang, J.; Zhang, L.; Xu, Menghong; Chen, J.; Gong, Ming; Liang, Xiaolong

doi:10.1016/j.mtadv.2022.100248

Cited by 9 publications

(8 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sonodynamic therapy has been widely applied as an effective and noninvasive cancer therapeutics. , Ultrasound can destroy tumor and generate tumor fragments, which can be used as antigens to form in situ vaccines and induce the systemic immune responses . Sonodynamic therapy can induce ICD to elicit effective immune responses and achieve better therapeutic results in combination with immunotherapy .…”

Section: Strategies To Enhance the Efficacy Of Mrna Cancer Vaccinesmentioning

confidence: 99%

mRNA Cancer Vaccines: Construction and Boosting Strategies

Liu,

Huang,

Yang

et al. 2023

ACS Nano

View full text Add to dashboard Cite

In late 2020, the U.S. Food and Drug Administration (FDA) approved a lipid-based mRNA vaccine for the prevention of COVID-19, which has pushed this field to be more closely studied and motivated researchers to delve deeper into mRNA therapeutics. To date, the research on mRNA cancer vaccines has been developed rapidly, and substantial hopeful therapeutic results have been achieved against various solid tumors in clinical trials. In this review, we first introduce three main components of mRNA cancer vaccines, including mRNA antigens, adjuvants, and delivery vectors. Engineering these components can optimize the therapeutic effects of mRNA cancer vaccines. For instance, appropriate modification of mRNA structure can alleviate the poor stability and innate immunogenicity of mRNA, and the use of mRNA delivery vectors can address the issues of low delivery efficiency in vivo. Second, we emphatically discuss some strategies to further improve the efficacy of mRNA cancer vaccines, namely modulating the immunosuppressive tumor environment, optimizing administration routes, achieving targeting delivery to intended tissues or organs, and employing combination therapy. These strategies can strengthen the tumor inhibitory ability of mRNA cancer vaccines and increase the possibility of tumor elimination. Finally, we point out some challenges in the clinical practice of mRNA cancer vaccines and offer our perspectives on future developments in this rapidly evolving field. It is anticipated that mRNA cancer vaccines will be rapidly developed for clinical cancer therapy in the near future.

show abstract

Section: Strategies To Enhance the Efficacy Of Mrna Cancer Vaccinesmentioning

confidence: 99%

mRNA Cancer Vaccines: Construction and Boosting Strategies

Liu,

Huang,

Yang

et al. 2023

ACS Nano

View full text Add to dashboard Cite

show abstract

“…Immunotherapy enhances the body’s immune response and inhibits immune escape [ 31 ]. Targeting macrophages holds great promise for cancer immunotherapy since macrophages account for 30% to 50% of the infiltrating immune cells in the tumor microenvironment (TME) compared to the low infiltration of T cells [ 32 ].…”

Section: Potential Prospects Of Lactb In Cancer Applicationsmentioning

confidence: 99%

LACTB, a Metabolic Therapeutic Target in Clinical Cancer Application

Ren

Huang

et al. 2022

Cells

View full text Add to dashboard Cite

Serine beta-lactamase-like protein (LACTB) is the only mammalian mitochondrial homolog evolved from penicillin-binding proteins and β-lactamases (PBP-βLs) in bacteria. LACTB, an active-site serine protease, polymerizes into stable filaments, which are localized to the intermembrane space (IMS) of mitochondrion and involved in the submitochondrial organization, modulating mitochondrial lipid metabolism. Cancer pathogenesis and progression are relevant to the alterations in mitochondrial metabolism. Metabolic reprogramming contributes to cancer cell behavior. This article (1) evidences the clinical implications of LACTB on neoplastic cell proliferation and migration and tumor growth and metastasis as well as LACTB’s involvement in chemotherapeutic and immunotherapeutic responses; (2) sketches the structural basis for LACTB activity and function; and (3) highlights the relevant regulatory mechanisms to LACTB. The abnormal expression of LACTB has been associated with clinicopathological features of cancer tissues and outcomes of anticancer therapies. With the current pioneer researches on the tumor-suppressed function, structural basis, and regulatory mechanism of LACTB, the perspective hints at a great appeal of enzymic property, polymerization, mutation, and epigenetic and post-translational modifications in investigating LACTB’s role in cancer pathogenesis. This perspective provides novel insights for LACTB as a metabolic regulator with potential to develop targeted cancer therapies or neoadjuvant therapeutic interventions.

show abstract

“…[ 16 ] On the one hand, SDT can generate ROS exclusively at tumor sites to induce immunogenic cell death (ICD) of tumor cells, which further promotes the release of tumor‐associated antigens (TAAs), activates dendritic cells (DCs), and enhances the immunogenicity of tumors for cancer sono‐immunotherapy. [ 17 ] On the other hand, SDT can synergize with various immunotherapeutic agents such as cancer vaccines, immune checkpoint inhibitors, immune agonists or inhibitors, and tumor immune microenvironment (TIME)‐modulating molecules to activate the antitumor immune response. [ 18 ] Thus, cancer sono‐immunotherapy has higher clinical translation potential compared with sole SDT or immunotherapies.…”

Section: Introductionmentioning

confidence: 99%

Organic Sonodynamic Materials for Combination Cancer Immunotherapy

Zhang

2023

Advanced Materials

View full text Add to dashboard Cite

Sonodynamic therapy (SDT) has been a promising non‐invasive therapeutic modality to treat deep‐seated tumors owing to the good tissue penetration ability and spatiotemporal controllability of ultrasound (US); however, the low sonodynamic activity and potential side effects greatly limit its clinical translation. Cancer immunotherapy that leverages the immune system to fight against cancer has great potential to synergize with SDT for the treatment of cancer with high efficiency and safety. In this review, we discuss the convergence of SDT with cancer immunotherapy to exert their merits and break through the limitations of combination cancer sono‐immunotherapy. We focus on the development and construction of organic materials with high sonodynamic activity and immunotherapeutic efficiency. These organic materials not only induce immunogenic cell death to improve tumor immunogenicity via SDT but also activate antitumor immunity via immuno‐oncology drug‐mediated immune pathway modulation. The combination of various immuno‐oncology drugs with organic sonosensitizers is categorized and discussed along with the prospects and challenges for clinical translation.This article is protected by copyright. All rights reserved

show abstract

Ultrasound-mediated immune regulation in tumor immunotherapy

Cited by 9 publications

References 77 publications

mRNA Cancer Vaccines: Construction and Boosting Strategies

mRNA Cancer Vaccines: Construction and Boosting Strategies

LACTB, a Metabolic Therapeutic Target in Clinical Cancer Application

Organic Sonodynamic Materials for Combination Cancer Immunotherapy

Contact Info

Product

Resources

About